Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis.

Triple negative breast cancer (TNBC) has a poor outcome due to the lack of beneficial therapeutic targets. To clarify the molecular mechanisms involved in the carcinogenesis of TNBC and to identify target molecules for novel anticancer drugs, we analyzed the gene expression profiles of 30 TNBCs as well as 13 normal epithelial ductal cells that were purified by laser-microbeam microdissection. We identified 301 and 321 transcripts that were significantly upregulated and downregulated in TNBC, respectively. In particular, gene expression profile analyses of normal human vital organs allowed us to identify 104 cancer-specific genes, including those involved in breast carcinogenesis such as NEK2, PBK and MELK. Moreover, gene annotation enrichment analysis revealed prominent gene subsets involved in the cell cycle, especially mitosis. Therefore, we focused on cell cycle regulators, asp (abnormal spindle) homolog, microcephaly-associated (Drosophila) (ASPM) and centromere protein K (CENPK) as novel therapeutic targets for TNBC. Small-interfering RNA-mediated knockdown of their expression significantly attenuated TNBC cell viability due to G1 and G2/M cell cycle arrest. Our data will provide a better understanding of the carcinogenesis of TNBC and could contribute to the development of molecular targets as a treatment for TNBC patients.

[1]  Jungsuk An,et al.  Epithelial–mesenchymal transition in breast cancer correlates with high histological grade and triple‐negative phenotype , 2012, Histopathology.

[2]  Ki-Chun Yoo,et al.  PTTG1 Oncogene Promotes Tumor Malignancy via Epithelial to Mesenchymal Transition and Expansion of Cancer Stem Cell Population* , 2012, The Journal of Biological Chemistry.

[3]  T. Putti,et al.  The Ubiquitin Peptidase UCHL1 Induces G0/G1 Cell Cycle Arrest and Apoptosis Through Stabilizing p53 and Is Frequently Silenced in Breast Cancer , 2012, PloS one.

[4]  S. Law,et al.  The ECM protein LTBP‐2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome , 2011, International journal of cancer.

[5]  A. Tangoku,et al.  Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer. , 2011, Anticancer research.

[6]  George S. Krasnov,et al.  Differential Expression of CHL1 Gene during Development of Major Human Cancers , 2011, PloS one.

[7]  J. Mackey,et al.  Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. , 2011, The American journal of pathology.

[8]  T. Arumugam,et al.  S100P: a novel therapeutic target for cancer , 2011, Amino Acids.

[9]  F. Lallemand,et al.  Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy , 2011, Molecular Cancer.

[10]  R. Cardiff,et al.  ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. , 2010, Cancer research.

[11]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[12]  Per Karlsson,et al.  Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma , 2010, Clinical Cancer Research.

[13]  M. Nagino,et al.  Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin , 2010, Cancer science.

[14]  Jian-ming Li,et al.  A five‐gene signature as a potential predictor of metastasis and survival in colorectal cancer , 2010, The Journal of pathology.

[15]  J. Baselga,et al.  Management of breast cancer with targeted agents: importance of heterogenicity , 2010, Nature Reviews Clinical Oncology.

[16]  W. Jin,et al.  UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs , 2010, Breast Cancer Research and Treatment.

[17]  J. Gray,et al.  The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer , 2010, Breast Cancer Research.

[18]  Yusuke Nakamura,et al.  Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. , 2009, Cancer research.

[19]  R. Bataille,et al.  Validation of UBE2C protein as a prognostic marker in node-positive breast cancer , 2009, British Journal of Cancer.

[20]  Ming-Tzu Tsai,et al.  SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. , 2009, Cancer research.

[21]  M. Nagino,et al.  Nek2 as a novel molecular target for the treatment of breast carcinoma , 2009, Cancer science.

[22]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[23]  J. Pumphrey,et al.  The TRAIL to targeted therapy of breast cancer. , 2009, Advances in cancer research.

[24]  T. Katagiri,et al.  Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells , 2008, Oncogene.

[25]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[27]  Paul S Mischel,et al.  Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells , 2008, Journal of neuroscience research.

[28]  A. Desai,et al.  KNL1 and the CENP-H/I/K complex coordinately direct kinetochore assembly in vertebrates. , 2007, Molecular biology of the cell.

[29]  Yusuke Nakamura,et al.  Involvement of kinesin family member 2C/mitotic centromere‐associated kinesin overexpression in mammary carcinogenesis , 2007, Cancer science.

[30]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[31]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[32]  Daniel Birnbaum,et al.  Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.

[33]  Yusuke Nakamura,et al.  Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells , 2007, Cancer science.

[34]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[35]  Yusuke Nakamura,et al.  Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family , 2007, Breast Cancer Research.

[36]  S. Horvath,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006, Proceedings of the National Academy of Sciences.

[37]  Yusuke Nakamura,et al.  PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. , 2006, Cancer research.

[38]  Q. Tao,et al.  Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. , 2006, Carcinogenesis.

[39]  A. Fry,et al.  Nek2 kinase in chromosome instability and cancer. , 2006, Cancer letters.

[40]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[41]  C. Pilarsky,et al.  Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. , 2004, Neoplasia.

[42]  J. Minna,et al.  Molecular Detection of Noninvasive and Invasive Bladder Tumor Tissues and Exfoliated Cells by Aberrant Promoter Methylation of Laminin-5 Encoding Genes , 2004, Cancer Research.

[43]  J. Isola,et al.  Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? , 2003, Clinical breast cancer.

[44]  T. Tomonaga,et al.  Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. , 2003, Cancer research.

[45]  Emanuel F. Petricoin,et al.  Medical applications of microarray technologies: a regulatory science perspective , 2002, Nature Genetics.

[46]  A. Báez,et al.  Cenp‐F gene amplification and overexpression in head and neck squamous cell carcinomas , 2001, Head & neck.

[47]  H. Ford,et al.  Cell Cycle-regulated Phosphorylation of the Human SIX1 Homeodomain Protein* , 2000, The Journal of Biological Chemistry.

[48]  D. Glover,et al.  Abnormal spindle protein, Asp, and the integrity of mitotic centrosomal microtubule organizing centers. , 1999, Science.

[49]  E. Tan,et al.  Autoantibody to centromere (kinetochore) in scleroderma sera. , 1980, Proceedings of the National Academy of Sciences of the United States of America.